On the whole, given the role of TCPTP in glucose metabolism by regulating insulin, leptin and other signaling pathways, this review considers that the development of specific and effective TCPTP inhibitors for individual cells, tissues or organs is a promising therapeutic strategy for diabetes or obesity. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.